{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:23Z","timestamp":1753892003481,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neoadjuvant chemotherapy (NAC) is a standard treatment strategy for breast cancer, with a commonly used regimen consisting of 4-cycle anthracycline and cyclophosphamide (AC) treatment followed sequentially by 4-cycle taxane (T) treatment. Variations in treatment efficacy are observed at different stages of AC-T regimen. Stratifying patients based on the efficacy variations could provide insights to prolong the cycle of AC or T treatment, potentially enhancing the overall efficacy of NAC. Therefore, this study aimed to evaluate the feasibility of developing magnetic resonance imaging (MRI) radiomic models for predicting the relative efficacy of AC versus T treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 190 breast cancer patients, who were randomly allocated into a training set (n=133) and a test set (n=57). All patients received NAC treatment consisting of four cycles of AC followed by four cycles of T. Breast MRI examinations were conducted before NAC (pre-NAC), before the fifth cycle (mid-NAC), and before surgery (post-NAC). Relative efficacy was defined by comparing tumor volume change rates between the AC and T treatment stages. Radiomic features were extracted from dynamic contrast-enhanced (DCE) and apparent diffusion coefficient (ADC) images based on the intratumoral and peritumoral regions at the pre-NAC and mid-NAC stages. Radiomic models were first developed, and hybrid models were then established by integrating radiomic and clinicopathological data to predict relative efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For radiomic models, the Delta model demonstrated effective discrimination of relative efficacy, achieving areas under the curve (AUCs) of 0.887 [95% confidence interval (CI): 0.816-0.930] in the training set and 0.757 (95% CI: 0.683-0.817) in the test set. For hybrid models, the Delta+clinicopath model showed improved performance, with AUCs of 0.887 (95% CI: 0.873-0.892) in the training set and 0.772 (95% CI: 0.744-0.786) in the test set. The Delta+clinicopath model also exhibited favorable calibration in both sets and provided a substantial clinical net benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The hybrid model is a reliable and reproducible tool for predicting the relative efficacy between AC and T treatments in breast cancer NAC. The model could help to stratify patients for personalized adjustment of NAC regimens.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1544833","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:12:10Z","timestamp":1747282330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting relative efficacy of anthracyclines and taxanes in breast cancer neoadjuvant AC-T chemotherapy using longitudinal MRI radiomic model"],"prefix":"10.3389","volume":"15","author":[{"given":"Kaiwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiulou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Zha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1178223420980377","DOI":"10.1177\/1178223420980377","article-title":"Neoadjuvant chemotherapy for breast cancer: past, present, and future","volume":"14","author":"Asaoka","year":"2020","journal-title":"Breast Cancer (Auckl)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100\u2008000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2021200134","article-title":"Breast MRI for evaluation of response to neoadjuvant therapy","volume":"41","author":"Reig","year":"2021","journal-title":"RadioGraphics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s44326-024-00038-7","article-title":"Breast cancer: agreement between residual tumor size after neoadjuvant chemotherapy measurement with different imaging methods and the histological data","volume":"11","author":"Fattacciu","year":"2024","journal-title":"J Med Imaging Intervent Radiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07122-8","article-title":"Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy","volume":"203","author":"Rajan","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/00031348231198108","article-title":"The role of MRI in assessing residual breast cancer after neoadjuvant chemotherapy","volume":"90","author":"Rezkallah","year":"2024","journal-title":"Am Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.910869","article-title":"Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1533033820916191","DOI":"10.1177\/1533033820916191","article-title":"The application of radiomics in breast MRI: A review","volume":"19","author":"Ye","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11547-021-01423-y","article-title":"Radiomics in breast MRI: current progress toward clinical application in the era of artificial intelligence","volume":"127","author":"Satake","year":"2022","journal-title":"Radiol Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101719","DOI":"10.1016\/j.xcrm.2024.101719","article-title":"Radiomics in breast cancer: Current advances and future directions","volume":"5","author":"Qi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1151500","article-title":"The value of DCE- MRI of the breast as a diagnostic tool in assessing amorphous calcifications in screening mammography","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0940","article-title":"Response-guided neoadjuvant chemotherapy for breast cancer","volume":"31","author":"Von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00104-9","article-title":"MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II\u2013III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study","volume":"25","author":"van der Voort","year":"2024","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.3390\/cancers14143515","article-title":"Delta-radiomics based on dynamic contrast-enhanced MRI predicts pathologic complete response in breast cancer patients treated with neoadjuvant chemotherapy","volume":"14","author":"Guo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27145","article-title":"Role of MRI to assess response to neoadjuvant therapy for breast cancer","volume":"52","author":"Reig","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10334-021-00941-0","article-title":"Multicontrast MRI-based radiomics for the prediction of pathological complete response to neoadjuvant chemotherapy in patients with early triple negative breast cancer","volume":"34","author":"Nemeth","year":"2021","journal-title":"MAGMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.662749","article-title":"Prediction of tumor shrinkage pattern to neoadjuvant chemotherapy using a multiparametric MRI-based machine learning model in patients with breast cancer","volume":"9","author":"Huang","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.05.010","article-title":"Evaluation of multiparametric MRI radiomics-based nomogram in prediction of response to neoadjuvant chemotherapy in breast cancer: A two-center study","volume":"23","author":"Wang","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1057841","article-title":"Multiparametric MRI radiomics fusion for predicting the response and shrinkage pattern to neoadjuvant chemotherapy in breast cancer","volume":"13","author":"Fan","year":"2023","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.211509","article-title":"Microcalcifications and peritumoral edema predict survival outcome in luminal breast cancer treated with neoadjuvant chemotherapy","volume":"304","author":"Kwon","year":"2022","journal-title":"Radiology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10612-y","article-title":"Association of peritumoral region features assessed on breast MRI and prognosis of breast cancer: a systematic review and meta-analysis","volume":"34","author":"Zhao","year":"2024","journal-title":"Eur Radiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-025-01969-1","article-title":"Predictive value of tumoral and peritumoral radiomic features in neoadjuvant chemotherapy response for breast cancer: a retrospective study","author":"Pesapane","year":"2025","journal-title":"Radiol Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v12i14","article-title":"MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer","volume":"12","author":"Kolios","year":"2021","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12034-w","article-title":"A noninvasive tool based on magnetic resonance imaging radiomics for the preoperative prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer","volume":"29","author":"Li","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.3390\/diagnostics13193031","article-title":"Machine learning predicts pathologic complete response to neoadjuvant chemotherapy for ER+HER2- breast cancer: integrating tumoral and peritumoral MRI radiomic features","volume":"13","author":"Park","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00432-024-05680-y","article-title":"Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer patients: use of MRI radiomics data from three regions with multiple machine learning algorithms","volume":"150","author":"Zheng","year":"2024","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1544833\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:12:11Z","timestamp":1747282331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1544833\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1544833"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1544833","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"article-number":"1544833"}}